These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 29035829)

  • 1. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
    Xu S; Ge J; Zhang Z; Zhou W
    Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met.
    Gao S; Zhao Z; Wu R; Wu L; Tian X; Zhang Z
    Biomed Pharmacother; 2019 Jan; 109():1406-1410. PubMed ID: 30551391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circular RNA_0000326 promotes bladder cancer progression via microRNA-338-3p/ETS Proto-Oncogene 1/phosphoinositide-3 kinase/Akt pathway.
    Chen Y; Wang D; Shu T; Sun K; Zhao J; Wang M; Huang Y; Wang P; Zheng H; Cai Z; Yang Z
    Bioengineered; 2021 Dec; 12(2):11410-11422. PubMed ID: 34889689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Over-expression of miR-151a-3p inhibits proliferation and migration of PC-3 prostate cancer cells].
    Zhang Y; Hao T; Zhang H; Wei P; Li X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Mar; 34(3):247-252. PubMed ID: 29773107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2.
    Teng P; Jiao Y; Hao M; Tang X
    J Cell Biochem; 2018 Jul; 119(7):5243-5252. PubMed ID: 29236322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-365 inhibits the progression of lung adenocarcinoma through targeting ETS1 and inactivating AKT/mTOR pathway.
    Tong L; Han WZ; Wang JL; Sun NN; Zhuang M
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4836-4845. PubMed ID: 32432746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
    Liu F; Zhao X; Qian Y; Zhang J; Zhang Y; Yin R
    Biomed Pharmacother; 2017 Dec; 96():229-237. PubMed ID: 28987947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2.
    He Y; Ge Y; Jiang M; Zhou J; Luo D; Fan H; Shi L; Lin L; Yang L
    Cell Physiol Biochem; 2018; 47(4):1465-1481. PubMed ID: 29949784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling.
    Li JZ; Wang ZL; Xu WH; Li Q; Gao L; Wang ZM
    Cancer Invest; 2016; 34(4):181-8. PubMed ID: 27031291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
    Meng S; Jian Z; Yan X; Li J; Zhang R
    Mol Med Rep; 2019 Sep; 20(3):2541-2548. PubMed ID: 31322251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
    Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
    Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways.
    Gu Z; You Z; Yang Y; Ding R; Wang M; Pu J; Chen J
    Bioengineered; 2021 Dec; 12(1):4719-4735. PubMed ID: 34338146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
    Liu S; Zhang Y; Huang C; Lin S
    J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
    Li J; You T; Jing J
    Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer.
    Lu R; Yang Z; Xu G; Yu S
    Biomed Pharmacother; 2018 Sep; 105():633-644. PubMed ID: 29898430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.